$SHPH

HRT FINANCIAL LP sold $100K of SHPH

HRT FINANCIAL LP sold 29,111 shares of Shuttle Pharmaceuticals Holdings, Inc. (SHPH) at an average of $3.45 ($3.33–$3.52, $0.10M total) across 2 trades over 2026-07-07 to 2026-07-08.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jul 9, 2026, 9:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 9:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SHPH
Neutral
medium confidence
Mentioned
$SHPH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SHPHNeutralLow
01

Why it matters

A large 10% owner’s open-market sale may slightly pressure sentiment, especially if investors interpret it as reduced confidence, but it is not accompanied by new guidance, trial results, or corporate actions.

02

Market read

Traders may monitor SHPH for any follow-on selling pressure or for stabilization after the disclosed sale window.

03

What to watch

The article does not state whether proceeds were for diversification, taxes, or other obligations, and it does not provide any concurrent company news.

Relevance 4/10Novelty 5/10Timing: filed 2026-07-09 after trades on 2026-07-07 to 2026-07-08

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Shuttle Pharmaceuticals Holdings, Inc.

Company-level read

Ticker impact

$SHPHNeutralMedium confidence
Context

HRT Financial LP, a 10% owner, sold 29,111 Shuttle Pharmaceuticals shares in open-market trades at $3.33 to $3.52.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental; watch for follow-on selling or stabilization after the sale window.

Evidence & confidence

The filing is a Form 4 open-market sale with no 10b5-1 plan stated, but the article provides no new operational or financial developments beyond the transaction details.

Market effects

No direct sector read-across; this is company-specific insider selling disclosure.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management by a large holder rather than a negative signal about Shuttle Pharmaceuticals prospects.

Key entities

  • Shuttle Pharmaceuticals Holdings, Inc.

    Subject of the Form 4 insider transaction; ticker SHPH.

  • HRT Financial LP

    Reported open-market sale of 29,111 shares across two trades.

Related articles